Evotec to Voluntarily Delist from NASDAQ
(Thomson Reuters ONE) - Corporate news announcement processed and transmitted by Hugin AS.The issuer is solely responsible for the content of this announcement. ------------------------------------------------------------------------------------ Hamburg, Germany - 10 November 2009: Evotec AG (Frankfurt StockExchange: EVT, TecDAX) a leading provider in the discovery anddevelopment of novel small molecule drugs today announced that itplans to voluntarily delist its American Depositary Shares from theNASDAQ stock market and concentrate its share trading on the recentlyre-entered TecDAX platform.Dr Werner Lanthaler, Chief Executive Officer of Evotec stated:"Evotec follows the trading behaviour of its shareholders therebyreducing unnecessary complexity in the capital market presence andrelated costs. Despite this delisting we intend to continuallyimprove the information and service quality for our globalshareholder base."Evotec has given formal notice to the NASDAQ of its intention tovoluntarily delist its American Depositary Shares. Evotec intends tofile a Form 25 with the NASDAQ on 20 November 2009 to initiate thedelisting which will become effective on 30 November 2009. As soonthereafter as the Company is eligible, the Company intends to file aForm 15 with the Securities and Exchange Commission to terminate theregistration of the American Depositary Shares and the underlyingordinary shares.During the second quarter of 2008 Evotec acquired Renovis and, in thecontext of this transaction, listed on NASDAQ. The Evotec ADSs arelisted on the NASDAQ Global Market under the trading symbol "EVTC".Based on the "Evotec 2012 - Action Plan to Focus and Grow" Evotecimplemented strict restructuring measures during the course of thesecond quarter 2009. As a consequence of these measures, Evotecclosed its US operations in South San Francisco, California, duringthe third quarter 2009.Contact: Dr Werner Lanthaler, Chief Executive Officer,Evotec AG, Tel.: +49.(0)40.56081-242, werner.lanthaler(at)evotec.comForward-Looking StatementsInformation set forth in this press release contains forward-lookingstatements, which involve a number of risks and uncertainties. Suchforward-looking statements include, but are not limited to,statements about our expectations and assumptions concerningregulatory, clinical and business strategies, the progress of ourclinical development programs and timing of the results of ourclinical trials, strategic collaborations and management's plans,objectives and strategies. These statements are neither promises norguarantees, but are subject to a variety of risks and uncertainties,many of which are beyond our control, and which could cause actualresults to differ materially from those contemplated in theseforward-looking statements. In particular, the risks anduncertainties include, among other things: risks that the Company maybe unable to reduce its cash burn through recent restructuring andcost containment measures and may not recognize the results of suchmeasures within the expected timeframe; risks that product candidatesmay fail in the clinic or may not be successfully marketed ormanufactured; the risk that we will not achieve the anticipatedbenefits of our collaborations, partnerships and acquisitions in thetimeframes expected, or at all; risks relating to our ability toadvance the development of product candidates currently in thepipeline or in clinical trials; our inability to further identify,develop and achieve commercial success for new products andtechnologies; the risk that competing products may be moresuccessful; our inability to interest potential partners in ourtechnologies and products; our inability to achieve commercialsuccess for our products and technologies; our inability to protectour intellectual property and the cost of enforcing or defending ourintellectual property rights; our failure to comply with regulationsrelating to our products and product candidates, including FDArequirements; the risk that the FDA may interpret the results of ourstudies differently than we have; the risk that clinical trials maynot result in marketable products; the risk that we may be unable tosuccessfully secure regulatory approval of and market our drugcandidates; and risks of new, changing and competitive technologiesand regulations in the U.S. and internationally.The list of risks above is not exhaustive. Our most recent AnnualReport on Form 20-F, filed with the Securities and ExchangeCommission, and other documents filed with, or furnished to theSecurities and Exchange Commission, contain additional factors thatcould impact our businesses and financial performance. We expresslydisclaim any obligation or undertaking to release publicly anyupdates or revisions to any such statements to reflect any change inour expectations or any change in events, conditions or circumstanceson which any such statement is based.http://hugin.info/131215/R/1353706/327931.pdf --- End of Message ---Evotec AGSchnackenburgallee 114 Hamburg GermanyWKN: 566480; ISIN: DE0005664809 ; Index: Prime All Share, CDAX, HDAX, MIDCAP, TECH All Share;Listed: Prime Standard in Frankfurter Wertpapierbörse, Freiverkehr in Börse Berlin, Freiverkehr in Bayerische Börse München, Freiverkehr in Börse Düsseldorf, Freiverkehr in Börse Stuttgart, Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg, Freiverkehr in Niedersächsische Börse zu Hannover, Regulierter Markt in Frankfurter Wertpapierbörse;
Datum: 10.11.2009 - 07:59 Uhr
Sprache: Deutsch
News-ID 8140
Anzahl Zeichen: 0
contact information:
Town:
London
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 213 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Evotec to Voluntarily Delist from NASDAQ"
steht unter der journalistisch-redaktionellen Verantwortung von
Evotec AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
